

# Investigating the neuropathology of obstructive sleep apnoea

<b>Submission date</b> 03/10/2016	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/01/2017	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 25/06/2021	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Obstructive sleep apnoea (OSA) is a common condition in which the upper airways (wind pipe) collapse repeatedly during sleep, stopping the flow of air into the lungs. This prevents the sufferer from being able to breathe properly while they are asleep, causing excessive sleepiness throughout their waking hours. OSA is usually treated using a continuous positive airway pressure (CPAP) machine. This involves the patient wearing a face mask during sleep which is connected to the machine which supplies a constant stream of air to help keep the airways open. Previous research has shown that the low blood oxygen levels affect thinking and feeling, and in some cases it may damage the brain cells involved with memory, attention, emotions and decision-making (cognitive function). The aim of this study is to investigate the relationship between the amount of oxygen in the blood and the loss (if any) of brain cells, as well as how the ability to perform complex tasks is affected in patients that suffer from sleep apnoea.

### Who can participate?

Adult men with untreated mild OSA who are experience excessive sleepiness.

### What does the study involve?

At the start of the study, participants are interviewed, provide blood and saliva samples, have their cognitive function tested and have two MRI brain scans and two PET-MR brain scans. The MMRI scan involves going into an MRI scanner (large tube) which uses strong magnetic fields and radiowaves to see the activity in the brain. The PET-MR scan is a MRI scanning is combined with another type of scanning called PET, which involves the injection of a radioactive tracer into the body which is picked up in the scan. Participants then return three months later after having been treated with CPAP as part of their normal care. At the three months visit, the initial tests are repeated in order to find out if the CPAP has caused any structural changes in the brain or affected cognitive function.

### What are the possible benefits and risks of participating?

There are no direct benefits of taking part, however some participants may find taking part in research rewarding, as they will be contributing to the development of medical knowledge that may benefit other people in the future. The main disadvantage of taking part in this study is the extra time taken to attend the hospital for the tests. Participants will be assisted with travel

arrangements to attend the tests. Some private medical insurers require to be notified of participation in research studies.

The interview involves discussing personal information and experiences that some people may find distressing. Participants will be informed that if they feel uncomfortable with any of the questions they do not have to answer them. Blood sampling can cause some discomfort, and there is a possibility that a small bruise may develop. In addition, participants may find the MRI scan to be claustrophobic or anxiety-causing and the PET scan to be uncomfortable as it involves a line being placed in a vein, which can cause pain, bruising and infection.

Where is the study run from?  
Nuffield House Sleep Centre (UK)

When is the study starting and how long is it expected to run for?  
June 2016 to October 2020

Who is funding the study?  
Wellcome Trust (UK)

Who is the main contact?  
Dr Nadia Gildeh  
nadia.gildeh@kcl.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Valentina Gnoni

**Contact details**  
Institute of Psychiatry, Psychology & Neuroscience  
King's College London  
16 De Crespigny Park  
London  
United Kingdom  
SE5 8AB  
+44 (0)7599002961  
valentina.gnoni@kcl.ac.uk

**Type(s)**  
Scientific

**Contact name**  
Dr Ivana Rosenzweig

**Contact details**  
Institute of Psychiatry, Psychology & Neuroscience  
King's College London  
16 De Crespigny Park  
London

United Kingdom  
SE5 8AB  
+44 (0)20 7848002  
ivana.1.rosenzweig@kcl.ac.uk

## **Additional identifiers**

**Protocol serial number**  
31311

## **Study information**

**Scientific Title**  
Investigating the Neuropathology of Obstructive Sleep Apnoea (INcOSA)

**Acronym**  
INcOSA

**Study objectives**  
The aim of this study is to investigate:  
1. How low blood oxygen levels affect brain cells, and how this affects the ability to perform memory tasks  
2. Whether impairments in brain functioning can be reversed if the breathing difficulties are treated with continuous positive airway pressure (CPAP)

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
London-Camberwell St Giles Research Ethics Committee, 14/07/2016, ref: 16/LO/0893

**Study design**  
Observational; Design type: Cohort

**Primary study design**  
Observational

**Study type(s)**  
Treatment

**Health condition(s) or problem(s) studied**  
Sleep apnoea

**Interventions**  
The total duration of participants in this research study will be 4 months. Participants will be recruited from sleep clinics at the Sleep Disorder's Centre, Guy's Hospital. Participants will have an initial interview and discussion regarding the study to assess whether they would like to take part. As part of usual practice they will have an initial medical assessment and examination.

In the first study visit, participants will undergo an overnight study as part of usual practice to assess the level of sleep apnoea and rule out any other sleep disorders. Following this, if a participant meets the criteria for the study a discussion and written consent will be taken formally for participation in the study. Participants will also be asked to provide a blood or saliva sample and complete some short questionnaires. Cognitive testing will then be performed and will last roughly 2 hours, after which participants will be transported to another site (King's College London, Centre for Neuroimaging Sciences) for an MRI brain scan (lasting roughly 1 hour).

At a second visit, a PET-MRI scan will be performed (Guy's and St Thomas' Hospital Trust) within 2 weeks of the initial assessment and overnight study/MRI scan. This will last approximately 1.5 hours.

Participants will then started on CPAP treatment for OSA as per usual clinical practice. This will be done within usual NHS wait times and there will not be any delay. Participants will receive follow up phone calls to ensure any issues are dealt with.

After 3 months of CPAP therapy participants will have a further overnight study to ensure treatment is adequate as part of standard care and following this will have a repeat MRI and PET scan, blood/saliva samples taken as well as cognitive testing. We will attempt to ensure this occurs in as few visits as possible and within 2 weeks of the overnight study.

Following the repeat studies after 3 months of treatment management will be taken over solely by the clinical sleep team with opportunity for a full debrief after the participants final visit. A letter will be sent within 2 weeks of the final visit thanking participants for their time and offering opportunity for further questions to be answered. No individual results will be produced due to anonymisation, however group results will be offered when analysis is complete. Travel and reasonable costs as well as compensation for time given will be provided.

## **Intervention Type**

Other

## **Primary outcome(s)**

Levels of neuroinflammation and discrete changes in brain morphology, physiology and cognition will be measured via MRI, PET-MRI imaging and cognitive testing (CANTAB battery) at baseline and after 3 months of CPAP treatment.

## **Key secondary outcome(s)**

Genetic analysis and linkage to clinical and neuroimaging data will be measured using biological samples (blood or saliva) which will be analysed and stored in the BioResource for Mental and Neurological Health at baseline and 3 months after CPAP treatment.

## **Completion date**

01/10/2020

## **Eligibility**

### **Key inclusion criteria**

1. Male patients
2. Untreated mild OSA (AHI>5events/hour and <10) or severe OSA (AHI>30events/hour)
3. Excessive sleepiness (ESS>9)
4. Aged 18- 65 years

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

Male

**Key exclusion criteria**

1. Female patients
2. Patients with other sleep disorders
3. Current or past neurological or psychiatric disease
4. Undertaking neuropharmacological treatment
5. History of alcohol or recreational drug abuse
6. Major organ failure
7. Professional drivers/shift workers
8. Unable to have MRI scan (e.g. too heavy (>200Kg) or who have ferromagnetic implants)
9. Inability to comprehend what is proposed
10. Inability to travel to the research sites

**Date of first enrolment**

27/09/2016

**Date of final enrolment**

01/04/2020

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**  
**Nuffield House Sleep Centre**  
Guy's Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT

## Sponsor information

**Organisation**  
King's College London

**ROR**  
<https://ror.org/0220mzb33>

## Funder(s)

**Funder type**  
Charity

**Funder Name**  
Wellcome Trust

**Alternative Name(s)**

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
International organizations

**Location**  
United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

**IPD sharing plan summary**

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes